Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28239560 | 0.88 | POLB (0.60) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL8758318 | 0.86 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL9733117 | 0.86 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL9584018 | 0.84 | PLA2G2A (0.61) | ALDH1A1LMNAHTR6 | |
| SCHEMBL1418988 | 0.84 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2HTTKMT2AMAPT | |
| SCHEMBL29377589 | 0.84 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2HTTKMT2AMAPT | |
| SCHEMBL797444 | 0.84 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL797443 | 0.84 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL28538675 | 0.84 | POLB (0.67) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL8685900 | 0.83 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047226-B | Matrine pyrrole and indole derivatives, and preparation method and application thereof | 广西大学 | 2020-11-03 | — | — | CN | claimed |
| CN-108358923-B | Sophoridine pyrrole and indole derivatives, and preparation method and application thereof | 广西大学 | 2020-11-03 | — | — | CN | claimed |
| CN-108358923-A | Sophoridine pyrroles, indole derivatives and the preparation method and application thereof | 广西大学 | 2018-08-03 | — | — | CN | claimed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| CN-103108871-B | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-09-10 | — | — | CN | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-103108871-A | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2013-05-15 | — | — | CN | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | ALDH1A1 68/4885SMN1; SMN2 4109/4885HTT 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.